25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.
8 citations
,
May 2025 in “Dermatology and Therapy” This review discusses the use of topical and intralesional corticosteroids for treating alopecia areata, highlighting their efficacy and safety but noting recurrence and pain as limitations; no new clinical results are reported.
2 citations
,
November 2024 in “Australian Journal of General Practice” This abstract highlights the urgent need for rigorous research, quality assessment tools, and health economics analyses to integrate DTC telemedicine with traditional primary care for improved healthcare quality and efficiency.
April 2025 in “Dermatology and Therapy” This study suggests that sustained hair regrowth is necessary to significantly change patient-reported psychosocial outcomes in alopecia areata, with time since regrowth being a critical factor in measuring adaptation.
July 2024 in “Dermatology and Therapy” This study found that individuals with black hair have a significantly higher risk of alopecia areata compared to those with dark brown hair, while lighter hair colors like red or blonde are associated with a lower risk.